Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Plasma H3.1 nucleosomes as biomarkers of infection, inflammation and organ failure

Wednesday, August 6, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The poster presented by Daan F.L. Filippini and colleagues discusses the potential of Plasma H3.1 nucleosomes as biomarkers for infection, inflammation, and organ failure. This research could enhance diagnostic capabilities in critical care settings, aiding in the timely identification of severe health issues.
Price reaction · baseline $12.8 (2025-08-05 close) · hit pre-market · 4 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
+4.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Research highlights potential biomarkers for critical health conditions.
  • Study may contribute to improved diagnostics for infections and organ failure.

Full Press Release Details

Poster titled: Plasma H3.1 nucleosomes as biomarkers of infection, inflammation and organ failure
Daan F.L. Filippini, Michael Jiang, Lina Kramer, Tom van der Poll, Olaf Cremer, Teddy Tun Win Hla, Andrew Retter, Lieuwe D.J. Bos

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What are Plasma H3.1 nucleosomes?

Plasma H3.1 nucleosomes are potential biomarkers for infection, inflammation, and organ failure.

Who conducted the research on H3.1 nucleosomes?

The research was conducted by Daan F.L. Filippini and a team of researchers.

What is the significance of this research?

This research may improve diagnostic capabilities for critical health conditions.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare biomarkers infection inflammation organ failure
Last updated: Aug 6, 2025

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk